Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03164291 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
A Phase 3 study, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
NCT03164291: Completed Phase 3 study, sponsored by The University of Texas Health Science Center at Tyler.
NCT03164291 is a Phase 3 study that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 170 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03164291, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
Study Summary
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
Interventions
- DRUG Rifabutin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 1984-06 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03164291
The ClinicalTrials.gov registry entry for NCT03164291 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). The listed sponsor is The University of Texas Health Science Center at Tyler, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifabutin is the first listed.
NCT03164291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03164291 about?
NCT03164291 is a clinical study titled "Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex". Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
What is the current status of trial NCT03164291?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 1984-06. Estimated completion is 2017-05-18.
What interventions are being tested in trial NCT03164291?
The interventions under investigation include: Rifabutin (DRUG).
Who is sponsoring clinical trial NCT03164291?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.